þ
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the fiscal year ended December 31, 2010 | ||
OR
|
||
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware (State or other jurisdiction of incorporation or organization) |
98-0424072 (I.R.S. Employer Identification Number) |
Universal Biosensors, Inc. 1 Corporate Avenue, Rowville, 3178, Victoria Australia (Address of principal executive offices) |
Telephone: +61 3 9213 9000 (Registrants telephone number, including area code) |
Not Applicable (Zip Code) |
Title of Each Class
|
Name of Each Exchange on Which Registered
|
|
None
|
Not applicable |
Large accelerated filer o
|
Accelerated filer þ |
Non-accelerated filer o (Do not check if a smaller reporting company) |
Smaller reporting company þ |
Title of Class
|
Number of Shares
|
|
Common Stock, US$.0001 par value
|
158,968,161 |
1
2
| our business and product development strategies; | |
| our expectations with respect to corporate collaborations or strategic alliances with respect to our tests in development, including revenues expected from such collaborations; | |
| our expectations with respect to the timing and amounts of revenues from our customers and partners; | |
| our expectations with respect to the services we provide to and, the development projects we undertake for, our customers and partners; | |
| our expectations with respect to sales of products we develop and the quantities of such products to be manufactured by us; | |
| our expectations with respect to regulatory submissions, approvals and market launches of products we develop or are involved in developing; | |
| our expectations with respect to our research and development programs and our associated research and development expenses; | |
| the ability to protect our owned or licensed intellectual property; and | |
| our estimates regarding our capital requirements, the sufficiency of our cash resources and our need for additional financing. |
3
ITEM 1. | BUSINESS. |
4
| seeking to enter into collaborative arrangements or strategic alliances with other life sciences companies or other industry participants to complete the development and commercialization of our non-blood glucose tests; | |
| manufacturing test strips for our customers and partners as required; | |
| extending the electrochemical cell technology by developing new tests; | |
| undertaking contract research and development work on behalf of our customers and partners; | |
| providing post market support services to our customers and partners. |
| seek to identify and then negotiate collaborative arrangements or strategic alliances with third parties with respect to one or more of our non-blood glucose programs; | |
| manufacture test strips to satisfy our customers and partners demand requirements; | |
| provide the necessary post-market support for our customers and partners; | |
| continue to undertake contract research and development work on behalf of our customers and partners; | |
| seek to develop additional products; | |
| advance our research and development activities with respect to our prothrombin time test, C-reactive protein test and D-dimer test up to a point where they provide credible evidence of the value for potential partners. |
5
6
Point-of-Care Test
|
Development Stage
|
Next Anticipated Milestones
|
||
Prothrombin time test
|
Development work undertaken since early
2005
Working prototype developed Test feasibility established and ready to enter formal development/validation Strip manufacturing equipment undergoing commissioning |
Test targeted to be ready to submit for
approval during the first quarter of 2012 Continue efforts to enter into collaborative arrangements or strategic alliances with a third party |
||
D-dimer test
|
Development work undertaken since early
2008
A minimum of two additional years of development/ product validation work required |
Develop working prototype Commence product validation in 2012 Establish manufacturing process Continue efforts to enter into collaborative arrangements or strategic alliances with a third party |
||
Immunoassay C-reactive protein test
|
Development work undertaken since
2004
Working prototype developed Optimization and improvement work continuing on this project |
Exploration of new design formats Continue efforts to enter into collaborative arrangements or strategic alliances with third parties |
7
8
Expiration |
||
Patent
|
Year | |
Apparatus and Method for Electrochemical Protease Sensor
(this patent family relates to a sensor to detect cleavage of an
electrochemical substrate for use in measuring blood or plasma
coagulation in assays such as prothrombin time and thrombin
potential)
|
Refer Note 1 | |
Electrochemical On-Board Control Detection (this patent
family relates to an on-board control system of a sensor,
wherein the control system can test/verify the viability of the
sensor)
|
Refer Note 2 | |
Electrochemical Cells (this patent family relates to an
electrochemical cell which enables levels of analytes such as
glucose to be measured whilst using a small volume of sample)
|
2015 | |
Electrochemical Cell (this patent family relates to a
method and an electrochemical biosensor for determining the
concentration of an analyte in a carrier)
|
2022 | |
Electrochemical Method (this patent family provides an
improved method and biosensor for determination of the
concentration of an analyte in a carrier which provides improved
accuracy, reliability and speed over prior techniques)
|
2016 | |
Electrochemical Method for Measuring Chemical Reaction Rates
(this patent family relates to the measurement of the
progress of a chemical reaction that generates an electroactive
reaction product that is subsequently detected at an electrode
amperometrically or coulometrically)
|
2023 | |
Electrochemical Cell Connector (this patent family
relates to a connector to provide electrical connection between
an electrochemical cell of a strip type sensor and meter
circuitry)
|
2026 | |
Biosensor Apparatus and Methods of Use
|
Refer Note 1 |
(1) | The patent application is either pending, allowed, or published | |
(2) | This patent family is due for national stage entry in October 2011 |
9
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Revenue from products
|
11,760,009 | 132,733 | | |||||||||
Revenue from services
|
6,420,027 | 2,850,071 | 3,121,754 | |||||||||
Research and development income
|
| 1,337,125 | 1,170,190 | |||||||||
Milestone payment
|
| 17,722,641 | | |||||||||
Interest income
|
1,192,889 | 809,459 | 2,542,060 | |||||||||
Fee income
|
| | 1,131,222 | |||||||||
Total income
|
19,372,925 | 22,852,029 | 7,965,226 | |||||||||
Income from LifeScan as a % of total income
|
94 | % | 96 | % | 68 | % |
10
11
12
13
| we may not be able to control the amount and timing of resources that our strategic partner/collaborators may devote to our products; | |
| our strategic partner/collaborators may experience financial difficulties; | |
| we may be required to relinquish important rights such as marketing and distribution rights; | |
| business combinations or significant changes in a collaborators business strategy may also adversely affect a collaborators willingness or ability to complete its obligations under any arrangement; | |
| a collaborator could independently move forward with a competing product developed either independently or in collaboration with others, including our competitors; and | |
| collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our products. |
14
15
16
17
18
19
| the division of our Board into classes whose terms expire at staggered intervals over a three year period and advance notice requirements for nominations to our Board and proposing matters that can be acted upon at shareholder meetings; | |
| the requirement that actions by our stockholders by written consent be unanimous; | |
| the ability of our Board to issue preferred stock. |
20
ITEM 1B. | UNRESOLVED STAFF COMMENTS. |
ITEM 2. | PROPERTIES. |
ITEM 3. | LEGAL PROCEEDINGS. |
ITEM 4. | [REMOVED AND RESERVED] |
ITEM 5. | MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. |
21
High A$ | Low A$ | |||||||
Fiscal Year 2010
|
||||||||
First Quarter
|
A$ | 2.02 | A$ | 1.60 | ||||
Second Quarter
|
A$ | 1.75 | A$ | 1.30 | ||||
Third Quarter
|
A$ | 1.68 | A$ | 1.40 | ||||
Fourth Quarter
|
A$ | 1.65 | A$ | 1.35 | ||||
Fiscal Year 2009
|
||||||||
First Quarter
|
A$ | 0.41 | A$ | 0.66 | ||||
Second Quarter
|
A$ | 0.56 | A$ | 1.20 | ||||
Third Quarter
|
A$ | 0.83 | A$ | 1.40 | ||||
Fourth Quarter
|
A$ | 1.30 | A$ | 1.98 |
22
Number of Holders that |
||||||||
Total Number of |
are United States |
|||||||
Date
|
Registered Holders | Residents | ||||||
At March 2, 2011
|
1,628 | 10 |
Number of Securities to be |
||||||||||||
Issued Upon Exercise of |
Weighted Average Exercise |
Number of Securities |
||||||||||
Outstanding Options, |
Price of Outstanding |
Remaining for Future |
||||||||||
Plan Category
|
Warrants and Rights | Options, Warrants and Rights | Issuance | |||||||||
(A$) | ||||||||||||
Equity compensation plans approved by security holders
|
8,539,704 | 0.93 | (1 | ) | ||||||||
Equity compensation plans not approved by security holders(2)
|
| | (1 | ) | ||||||||
Total
|
8,539,704 | 0.93 | ||||||||||
(1) | The number of employee options able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. The Listing Rules of ASX generally prohibit companies whose securities are quoted on the ASX from issuing securities exceeding 15% of issued share capital in any 12 month period, without stockholder approval. | |
(2) | On February 24, 2011 our Board of Directors approved the appointment of Mr. Paul Wright as a director and the Chief Executive Officer of the Company effective as of March 1, 2011. At the time of the Boards approval of his appointment, the Board also approved a long term incentive to Mr. Paul Wright in the form of a grant of 2,300,000 market price employee options under the Companys Employee Option Plan, subject to stockholder approval in relation to the proposed grant. The 2,300,000 employee options are proposed to be granted for no cash consideration and with an exercise price of A$1.38. |
23
Number of Options |
||||||||||||
Exercised and |
||||||||||||
Corresponding Number |
||||||||||||
Period Ending
|
of Shares Issued | Option Exercise Price | Proceeds Received | |||||||||
(A$) | ||||||||||||
2008
|
||||||||||||
May, 2008
|
18,124 | A$ | 0.35 | 5,047 | ||||||||
2009
|
||||||||||||
August, 2009
|
36,248 | A$ | 0.31 | 11,221 | ||||||||
September, 2009
|
25,374 | A$ | 0.31 | 7,853 | ||||||||
November, 2009
|
13,332 | A$ | 0.89 | 11,865 | ||||||||
November, 2009
|
25,373 | A$ | 0.28 | 7,059 | ||||||||
November, 2009
|
8,000 | A$ | 0.70 | 5,600 | ||||||||
November, 2009
|
30,000 | A$ | 1.18 | 35,400 | ||||||||
138,327 | 78,998 | |||||||||||
2010
|
||||||||||||
February, 2010
|
23,333 | A$ | 0.89 | 20,766 | ||||||||
February, 2010
|
20,000 | A$ | 0.94 | 18,800 | ||||||||
February, 2010
|
4,000 | A$ | 0.50 | 2,000 | ||||||||
February, 2010
|
18,124 | US$ | 0.26 | 5,104 | ||||||||
February, 2010
|
13,332 | A$ | 1.18 | 15,732 | ||||||||
February, 2010
|
18,124 | US$ | 0.22 | 4,489 | ||||||||
February, 2010
|
33,333 | Nil | | |||||||||
March, 2010
|
6,666 | A$ | 0.89 | 5,933 | ||||||||
March, 2010
|
6,666 | A$ | 0.70 | 4,666 | ||||||||
March, 2010
|
2,000 | A$ | 0.94 | 1,880 | ||||||||
May, 2010
|
12,500 | Nil | | |||||||||
June, 2010
|
6,667 | A$ | 0.94 | 6,267 | ||||||||
June, 2010
|
20,000 | US$ | 0.22 | 4,040 | ||||||||
August, 2010
|
25,374 | US$ | 0.26 | 8,381 | ||||||||
August, 2010
|
20,000 | A$ | 1.18 | 23,600 | ||||||||
August, 2010
|
13,332 | A$ | 0.89 | 11,865 | ||||||||
August, 2010
|
6,667 | A$ | 0.94 | 6,267 | ||||||||
September, 2010
|
13,333 | A$ | 0.94 | 12,533 | ||||||||
September, 2010
|
8,000 | A$ | 0.70 | 5,600 | ||||||||
September, 2010
|
16,666 | A$ | 1.20 | 19,999 | ||||||||
September, 2010
|
3,333 | A$ | 0.94 | 3,133 | ||||||||
October, 2010
|
960,560 | US$ | 0.26 | 256,018 | ||||||||
October, 2010
|
45,000 | A$ | 1.18 | 53,100 | ||||||||
October, 2010
|
100,000 | A$ | 0.89 | 89,000 | ||||||||
November, 2010
|
181,238 | US$ | 0.26 | 47,430 | ||||||||
November, 2010
|
28,000 | A$ | 1.18 | 33,040 | ||||||||
November, 2010
|
40,000 | A$ | 0.89 | 35,600 | ||||||||
November, 2010
|
21,333 | A$ | 0.94 | 20,053 | ||||||||
1,667,581 | 715,296 | |||||||||||
24
Market Value of |
||||||||
Number of Restricted |
Restricted Shares |
|||||||
Shares Issued | Issued | |||||||
November, 2009
|
40,670 | A$ | 69,952 | |||||
May, 2010
|
581 | A$ | 999 | |||||
November, 2010
|
47,400 | A$ | 74,892 |
ITEM 6. | SELECTED FINANCIAL DATA. |
Years Ended December 31, | ||||||||||||||||||||
2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||
A$ | A$ | A$ | A$ | A$ | ||||||||||||||||
Revenue
|
||||||||||||||||||||
Revenue from products
|
$ | 11,760,009 | $ | 132,733 | $ | | $ | | $ | | ||||||||||
Revenue from services
|
6,420,027 | 2,850,071 | 3,121,754 | | | |||||||||||||||
Research and development income
|
| 1,337,125 | 1,170,190 | 1,192,015 | 2,654,280 | |||||||||||||||
Milestone payment
|
| 17,722,641 | | | | |||||||||||||||
Total revenue
|
18,180,036 | 22,042,570 | 4,291,944 | 1,192,015 | 2,654,280 | |||||||||||||||
Operating costs & expenses
|
||||||||||||||||||||
Cost of goods sold(1)
|
10,801,062 | 458,162 | | | | |||||||||||||||
Cost of services
|
1,481,674 | 169,241 | 3,121,754 | | | |||||||||||||||
Research and development (2 and 3)
|
6,482,150 | 14,898,072 | 11,585,258 | 7,157,216 | 3,466,604 | |||||||||||||||
General and administrative(4)
|
7,185,550 | 5,635,569 | 5,510,127 | 4,226,757 | 2,511,182 | |||||||||||||||
Total operating costs & expenses
|
25,950,436 | 21,161,044 | 20,217,139 | 11,383,973 | 5,977,786 | |||||||||||||||
Profit/(loss) from operations
|
(7,770,400 | ) | 881,526 | (15,925,195 | ) | (10,191,958 | ) | (3,323,506 | ) | |||||||||||
Other income/(expense)
|
||||||||||||||||||||
Interest income
|
1,192,889 | 809,459 | 2,542,060 | 1,440,102 | 443,769 | |||||||||||||||
Interest expense
|
| (9,636 | ) | (9,489 | ) | | | |||||||||||||
Fee income
|
| | 1,131,222 | | | |||||||||||||||
Other
|
(33,014 | ) | (250,886 | ) | 265,310 | (210,382 | ) | 87,076 | ||||||||||||
Total other income/(expense)
|
1,159,875 | 548,937 | 3,929,103 | 1,229,720 | 530,845 | |||||||||||||||
Net profit/(loss) before tax
|
(6,610,525 | ) | 1,430,463 | (11,996,092 | ) | (8,962,238 | ) | (2,792,661 | ) | |||||||||||
Income tax benefit/(expense)
|
| | 206 | 145,000 | (163,000 | ) | ||||||||||||||
Net profit/(loss)
|
$ | (6,610,525 | ) | $ | 1,430,463 | $ | (11,995,886 | ) | $ | (8,817,238 | ) | $ | (2,955,661 | ) | ||||||
25
Years Ended December 31, | ||||||||||||||||||||
2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||
A$ | A$ | A$ | A$ | A$ | ||||||||||||||||
Basic net profit/(loss) per share
|
$ | (0.04 | ) | $ | 0.01 | $ | (0.08 | ) | $ | (0.07 | ) | $ | (0.06 | ) | ||||||
Average weighted number of shares used as denominator in
calculating basic net profit/(loss) per share
|
157,584,044 | 157,013,578 | 156,970,679 | 129,637,286 | 49,408,822 | |||||||||||||||
Diluted net profit/(loss) per share
|
$ | (0.04 | ) | $ | 0.01 | $ | (0.08 | ) | $ | (0.07 | ) | $ | (0.06 | ) | ||||||
Average weighted number of shares used as denominator in
calculating diluted net profit/(loss) per share
|
157,584,044 | 161,354,802 | 156,970,679 | 129,637,286 | 49,408,822 |
1 Includes non-cash compensation expense (cost of goods sold)
|
$ | 168,512 | $ | 21,207 | $ | | $ | | $ | | ||||||||||
2 Net of research grant income in these amounts
|
$ | | $ | | $ | 300,613 | $ | 872,513 | $ | 578,653 | ||||||||||
3 Includes non-cash compensation expense (research and
development)
|
$ | 859,551 | $ | 653,474 | $ | 661,497 | $ | 339,882 | $ | 147,373 | ||||||||||
4 Includes non-cash compensation expense (general and
administrative)
|
$ | 648,940 | $ | 404,090 | $ | 299,611 | $ | 277,833 | $ | 273,694 |
Years Ended December 31, | ||||||||||||||||||||
2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||
A$ | A$ | A$ | A$ | A$ | ||||||||||||||||
Balance Sheet Data:
|
||||||||||||||||||||
Cash and cash equivalents
|
23,271,766 | 31,291,011 | 28,334,864 | 41,958,285 | 30,184,756 | |||||||||||||||
Total assets
|
53,837,949 | 56,083,468 | 52,505,321 | 63,512,160 | 37,879,601 | |||||||||||||||
Long-term debt
|
| | | | | |||||||||||||||
Convertible preference shares(1)
|
| | | | | |||||||||||||||
Total stockholders (deficit) equity
|
47,219,079 | 51,314,002 | 48,703,230 | 59,749,624 | 35,281,927 |
(1) | Convertible preference shares were converted to shares of common stock immediately prior to the issue of shares in our initial public offering in Australian and concurrent US private placement in December 2006. |
ITEM 7. | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
26
ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
Year Ended December 31, 2010 | ||||||||||||||||
Quarter |
Quarter |
Quarter |
Quarter |
|||||||||||||
Ended |
Ended |
Ended |
Ended |
|||||||||||||
March 31 | June 30 | September 30 | December 31 | |||||||||||||
A$ | A$ | A$ | A$ | |||||||||||||
Revenue
|
||||||||||||||||
Revenue from products
|
$ | 1,524,813 | $ | 1,359,584 | $ | 3,202,873 | $ | 5,672,739 | ||||||||
Revenue from services
|
1,893,133 | 1,403,779 | 1,785,331 | 1,337,784 | ||||||||||||
Research and development income
|
| | | | ||||||||||||
Milestone payment
|
| | | | ||||||||||||
Total revenue
|
3,417,946 | 2,763,363 | 4,988,204 | 7,010,523 | ||||||||||||
Operating costs & expenses
|
||||||||||||||||
Cost of goods sold(1)
|
1,538,436 | 1,936,716 | 3,136,390 | 4,189,520 | ||||||||||||
Cost of services
|
246,064 | 247,190 | 376,398 | 612,022 | ||||||||||||
Research and development (2 and 3)
|
1,554,227 | 1,799,551 | 1,543,482 | 1,584,890 | ||||||||||||
General and administrative(4)
|
1,469,609 | 1,788,984 | 1,675,868 | 2,251,089 | ||||||||||||
Total operating costs & expenses
|
4,808,336 | 5,772,441 | 6,732,138 | 8,637,521 | ||||||||||||
Profit/(loss) from operations
|
(1,390,390 | ) | (3,009,078 | ) | (1,743,934 | ) | (1,626,998 | ) | ||||||||
Other income/(expense)
|
||||||||||||||||
Interest income
|
305,019 | 327,949 | 289,296 | 270,625 | ||||||||||||
Interest expense
|
| | | | ||||||||||||
Fee income
|
| | | | ||||||||||||
Other
|
(10,291 | ) | 153,984 | (47,473 | ) | (129,234 | ) | |||||||||
Total other income/(expense)
|
294,728 | 481,933 | 241,823 | 141,391 | ||||||||||||
Net profit/(loss) before tax
|
(1,095,662 | ) | (2,527,145 | ) | (1,502,111 | ) | (1,485,607 | ) | ||||||||
Income tax benefit/(expense)
|
| | | | ||||||||||||
Net profit/(loss)
|
$ | (1,095,662 | ) | $ | (2,527,145 | ) | $ | (1,502,111 | ) | $ | (1,485,607 | ) | ||||
Basic and diluted net loss per share
|
$ | (0.01 | ) | $ | (0.02 | ) | $ | (0.01 | ) | $ | (0.01 | ) | ||||
Average weighted number of shares used as denominator
|
157,229,023 | 157,307,199 | 157,378,290 | 158,403,507 | ||||||||||||
Notes:
|
||||||||||||||||
1 Includes non-cash compensation expense (cost of goods sold)
|
$ | 40,688 | $ | 45,051 | $ | 28,489 | $ | 54,284 | ||||||||
2 Net of research grant income in these amounts
|
$ | | $ | | $ | | $ | | ||||||||
3 Includes non-cash compensation expense (research and
development)
|
$ | 245,968 | $ | 272,343 | $ | 172,215 | $ | 169,025 | ||||||||
4 Includes non-cash compensation expense (general and
administrative)
|
||||||||||||||||
$ | 172,130 | $ | 219,029 | $ | 129,969 | $ | 127,812 |
27
Year Ended December 31, 2009 | ||||||||||||||||
Quarter |
Quarter |
Quarter |
Quarter |
|||||||||||||
Ended |
Ended |
Ended |
Ended |
|||||||||||||
March 31 | June 30 | September 30 | December 31 | |||||||||||||
A$ | A$ | A$ | A$ | |||||||||||||
Revenue
|
||||||||||||||||
Revenue from products
|
$ | | $ | | $ | | $ | 132,733 | ||||||||
Revenue from services
|
1,467,464 | 312,590 | 819,181 | 250,836 | ||||||||||||
Research and development income
|
388,319 | 349,848 | 310,945 | 288,013 | ||||||||||||
Milestone payment
|
| | | 17,722,641 | ||||||||||||
Total revenue
|
1,855,783 | 662,438 | 1,130,126 | 18,394,223 | ||||||||||||
Operating costs & expenses
|
||||||||||||||||
Cost of goods sold(1)
|
| | | 458,162 | ||||||||||||
Cost of services
|
14,835 | 47,285 | 80,136 | 26,985 | ||||||||||||
Research and development(2)
|
3,233,635 | 4,104,205 | 3,681,701 | 3,878,531 | ||||||||||||
General and administrative(3)
|
1,190,592 | 1,395,286 | 1,543,305 | 1,506,386 | ||||||||||||
Total operating costs & expenses
|
4,439,062 | 5,546,776 | 5,305,142 | 5,870,064 | ||||||||||||
Profit/(loss) from operations
|
(2,583,279 | ) | (4,884,338 | ) | (4,175,016 | ) | 12,524,159 | |||||||||
Other income/(expense)
|
||||||||||||||||
Interest income
|
267,074 | 193,184 | 161,041 | 188,160 | ||||||||||||
Interest expense
|
(3,613 | ) | (3,614 | ) | (2,409 | ) | | |||||||||
Fee income
|
| | | | ||||||||||||
Other
|
(33,778 | ) | 52,265 | 5,368 | (274,741 | ) | ||||||||||
Total other income/(expense)
|
229,683 | 241,835 | 164,000 | (86,581 | ) | |||||||||||
Net profit/(loss) before tax
|
(2,353,596 | ) | (4,642,503 | ) | (4,011,016 | ) | 12,437,578 | |||||||||
Income tax benefit/(expense)
|
| | | | ||||||||||||
Net profit/(loss)
|
$ | (2,353,596 | ) | $ | (4,642,503 | ) | $ | (4,011,016 | ) | $ | 12,437,578 | |||||
Basic net profit/(loss) per share
|
$ | (0.01 | ) | $ | (0.03 | ) | $ | (0.03 | ) | $ | 0.08 | |||||
Average weighted number of shares used as denominator in
calculating basic net profit/(loss) per share
|
156,976,936 | 156,976,936 | 157,004,871 | 157,094,376 | ||||||||||||
Diluted net profit/(loss) per share
|
$ | (0.01 | ) | $ | (0.03 | ) | $ | (0.03 | ) | $ | 0.08 | |||||
Average weighted number of shares used as denominator in
calculating diluted net profit/(loss) per share
|
156,976,936 | 156,976,936 | 157,004,871 | 161,828,109 | ||||||||||||
Notes:
|
||||||||||||||||
1 Includes non-cash compensation expense (cost of goods
sold)
|
$ | | $ | | $ | | $ | 21,207 | ||||||||
2 Includes non-cash compensation expense (research and
development)
|
$ | 95,997 | $ | 81,024 | $ | 229,637 | $ | 246,816 | ||||||||
3 Includes non-cash compensation expense (general and
administrative)
|
$ | 44,451 | $ | 35,506 | $ | 172,253 | $ | 151,880 |
28
ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE |
ITEM 9A. | CONTROLS AND PROCEDURES |
29
| Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and the dispositions of the assets of the Company; | |
| Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and the board of directors of the Company; and | |
| Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Companys assets that could have a material effect on the financial statements. |
/s/ Andrew Denver
|
/s/ Salesh Balak | |
Andrew Denver Principal Executive Officer |
Salesh Balak Principal Financial Officer |
30
31
ITEM 9B. | OTHER INFORMATION |
ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. |
ITEM 11. | EXECUTIVE COMPENSATION. |
ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. |
32
ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. |
ITEM 14. | PRINCIPAL ACCOUNTING FEES AND SERVICES. |
ITEM 15. | EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULES. |
(a)(1) | Financial Statements |
Report of Independent Registered Public Accounting Firm
|
F-11 | |||
Consolidated Balance Sheets
|
F-13 | |||
Consolidated Statements of Operations
|
F-14 | |||
Consolidated Statements of Stockholders Equity and
Comprehensive Income
|
F-15 | |||
Consolidated Statements of Cash Flows
|
F-16 | |||
Notes to Consolidated Financial Statements
|
F-17 |
(a)(2) | Financial Statement Schedules Schedule II Valuation and Qualifying Accounts. All other schedules are omitted because of the absence of the conditions under which they are required or because the required information is included elsewhere in the financial statements. |
(a)(3) | and (b) Exhibits Refer below. |
Exhibit |
||||||
Number
|
Description
|
Location
|
||||
1 | .0 | Underwriting Agreement, by and between Universal Biosensors, Inc. and Wilson HTM Corporate Finance Limited dated November 9, 2007. | Incorporated by reference to our Current Report on Form 8-K filed on November 16, 2007 as Exhibit 1.1. | |||
3 | .1 | Amended and restated articles of incorporation dated December 5, 2006. | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 3.1. | |||
3 | .2 | Amended and restated by-laws dated December 5, 2006. | Incorporated by reference to our Amendment No. 5 to Form 10 filed on April 29, 2008 as Exhibit 3.2. | |||
10 | .1 | License Agreement between LifeScan and Universal Biosensors, Inc effective April 1, 2002, as amended on October 25, 2007, December 5, 2005 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.1. October 2007 amendment incorporated by reference to our Form 10-Q filed on November 14, 2007 as Exhibit 10.2. |
33
Exhibit |
||||||
Number
|
Description
|
Location
|
||||
10 | .2 | Development and Research Agreement by and between Universal Biosensors, Inc and LifeScan, Inc dated April 1, 2002 as amended on October 29, 2007, June 1, 2007, December 7, 2005, December 21, 2004 and March 31, 2004 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.2. June 2007 amendment incorporated by reference to our Amendment No. 2 to Form 10 filed on June 12, 2007 as Exhibit 10.2. October 2007 amendment incorporated by reference to our Form 10-Q filed on November 14, 2007 as Exhibit 10.3. | |||
10 | .3 | Form of indemnity agreement entered into with directors of us, our chief financial officer and company secretary | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.3. | |||
10 | .4 | Lease of premises 1 Corporate Avenue, Rowville Victoria Australia by and between Universal Biosensors Pty Ltd and Heyram Properties Pty Ltd. | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.5. | |||
10 | .5 | AusIndustry, R&D Start Program Agreement, effective February 25, 2005 (particular and general conditions) | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.6. | |||
10 | .6 | Employee Option Plan | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.7 | |||
10 | .7 | Employment agreement between Universal Biosensors Pty Ltd and Mr. Salesh Balak effective November 27, 2006 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.8 | |||
10 | .8 | Employment agreement between Universal Biosensors Pty Ltd and Mr. Garry Chambers effective April 1, 2006 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.9 | |||
10 | .9 | Employment agreement between Universal Biosensors Pty Ltd and Dr Ronald Chatelier dated April 1, 2006 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.10 | |||
10 | .10 | Employment agreement between Universal Biosensors Pty Ltd and Dr Alastair Hodges effective April 1, 2006 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.11 | |||
10 | .11 | Employment agreement between Universal Biosensors Pty Ltd and Mr. Adrian Oates dated August 15, 2007 | Incorporated by reference to our Form 10-K filed on March 16, 2010 as Exhibit 10.12 | |||
10 | .12 | Master Services and Supply Agreement by and between Universal Biosensors Pty Ltd, Universal Biosensors, Inc. and LifeScan, Inc. dated October 29, 2007 | Incorporated by reference to our Quarterly Report on Form 10-Q filed on November 14, 2007 as Exhibit 10.1. Confidentiality treatment has been granted for portions of this exhibit. These confidential portions have been omitted and were filed separately with the SEC. |
34
Exhibit |
||||||
Number
|
Description
|
Location
|
||||
10 | .13 | First Amendment to the Master services and Supply Agreement dated December 11, 2008 (which amends the Master Services and Supply Agreement by and between Universal Biosensors Pty Ltd, Universal Biosensors, Inc. and LifeScan, Inc. dated October 29, 2007 and filed on November 14, 2007 as Exhibit 10.1 to our Quarterly Report on Form 10-Q) | Incorporated by reference to our Annual Report on Form 10-K filed on March 30, 2009 as Exhibit 10.14 | |||
10 | .14 | Second Services Addendum - manufacturing Process Support (which amends the Master Services and Supply Agreement by and between Universal Biosensors Pty Ltd, Universal Biosensors, Inc. and LifeScan, Inc. dated October 29, 2007 incorporated by reference to our Quarterly Report on Form 10-Q filed on November 14, 2007 as Exhibit 10.1.) | Incorporated by reference to our Annual Report on Form 10-K filed on March 30, 2009 as Exhibit 10.15 | |||
10 | .15 | Advanced Care Enhanced Product Agreement (which is an addendum to the Amended and Restated Master Services and Supply Agreement filed on August 7, 2009 as Exhibit 10.3 to our Quarterly Report on Form 10-Q) | Incorporated by reference to our Quarterly Report on Form 10-Q filed on August 7, 2009 as Exhibit 10.1. Confidentiality treatment has been granted for portions of this exhibit. These confidential portions have been omitted and were filed separately with the SEC. | |||
10 | .16 | Fifth Amendment to Development and Research Agreement (which amends the Development and Research Agreement by and between Universal Biosensors, Inc. and LifeScan, Inc. dated April 1, 2002 and filed on April 30, 2007 as Exhibit 10.2 to our Form 10, the Amendment to the Development and Research Agreement filed on June 12 as Exhibit 10.2 to Amendment No. 2 to our Form 10 and the Amendment to Development and Research Agreement filed on November 14, 2007 as Exhibit 10.3 to our Quarterly Report on Form 10-Q. | Incorporated by reference to our Quarterly Report on Form 10-Q filed on August 7, 2009 as Exhibit 10.2. |
35
Exhibit |
||||||
Number
|
Description
|
Location
|
||||
10 | .17 | Amended and Restated Master Services and Supply Agreement (which amends and restates the Master Services and Supply Agreement by and between Universal Biosensors Pty. Ltd., Universal Biosensors, Inc., and LifeScan, Inc. dated October 29, 2007 filed on November 14, 2007 as Exhibit 10.1 to our Quarterly Report on Form 10-Q and the First Amendment to the Master Services and Supply Agreement filed on March 30, 2009 as Exhibit 10.14 to our Annual Report on Form 10-K) | Incorporated by reference to our Quarterly Report on Form 10-Q filed on August 7, 2009 as Exhibit 10.3. Confidentiality treatment has been granted for portions of this exhibit. These confidential portions have been omitted and were filed separately with the SEC. | |||
10 | .18 | Manufacturing Initiation Payment Addendum to Master Services and Supply Agreement (which is an addendum to the Amended and Restated Master Services and Supply Agreement filed on August 7, 2009 as Exhibit 10.3 to our Quarterly Report on Form 10-Q) | Incorporated by reference to our Quarterly Report on Form 10-Q filed on August 7, 2009 as Exhibit 10.4. Confidentiality treatment has been granted for portions of this exhibit. These confidential portions have been omitted and were filed separately with the SEC. | |||
10 | .19 | Employment agreement between Universal Biosensors Pty Ltd and Mr. Andrew Denver dated September 9, 2010 | Incorporated by reference to our Current Report on Form 8-K/A filed on December 22, 2010 as Exhibit 10.1. | |||
13 | .0 | Annual Report | Filed herewith | |||
14 | .0 | Code of Ethics | Incorporated by reference to our Annual Report on Form 10-K filed on March 28, 2008 as Exhibit 14.0 | |||
21 | .0 | List of Subsidiaries | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 21.0 | |||
24 | .0 | Power of Attorney | Included on signature page | |||
31 | .1 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act | Filed herewith | |||
31 | .2 | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act | Filed herewith | |||
32 | .0 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act | Filed herewith |
36
By: |
/s/ Andrew
Denver
|
Signature
|
Title
|
Date
|
||||
/s/ Andrew
Denver Andrew Denver |
Interim Chief Executive Officer and Chairman (Principal Executive Officer) |
March 10, 2011 | ||||
/s/ Salesh
Balak Salesh Balak |
Chief Financial Officer (Principal Financial Officer) |
March 10, 2011 | ||||
/s/ Denis
Hanley Denis Hanley |
Director | March 10, 2011 | ||||
/s/ Andrew
Jane Andrew Jane |
Director | March 10, 2011 | ||||
/s/ Elizabeth
Wilson Elizabeth Wilson |
Director | March 10, 2011 | ||||
/s/ Colin
Adam Colin Adam |
Director | March 10, 2011 | ||||
/s/ Marshall
Heinberg Marshall Heinberg |
Director | March 10, 2011 | ||||
/s/ Paul
Wright Paul Wright |
Director | March 10, 2011 |
37
Exhibit |
||||||
Number |
Description
|
Location
|
||||
1 | .0 | Underwriting Agreement, by and between Universal Biosensors, Inc. and Wilson HTM Corporate Finance Limited dated November 9, 2007. | Incorporated by reference to our Current Report on Form 8-K filed on November 16, 2007 as Exhibit 1.1. | |||
3 | .1 | Amended and restated articles of incorporation dated December 5, 2006. | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 3.1. | |||
3 | .2 | Amended and restated by-laws dated December 5, 2006. | Incorporated by reference to our Amendment No. 5 to Form 10 filed on April 29, 2008 as Exhibit 3.2. | |||
10 | .1 | License Agreement between LifeScan and Universal Biosensors, Inc effective April 1, 2002, as amended on October 25, 2007, December 5, 2005 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.1. October 2007 amendment incorporated by reference to our Form 10-Q filed on November 14, 2007 as Exhibit 10.2. | |||
10 | .2 | Development and Research Agreement by and between Universal Biosensors, Inc and LifeScan, Inc dated April 1, 2002 as amended on October 29, 2007, June 1, 2007, December 7, 2005, December 21, 2004 and March 31, 2004 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.2. June 2007 amendment incorporated by reference to our Amendment No. 2 to Form 10 filed on June 12, 2007 as Exhibit 10.2. October 2007 amendment incorporated by reference to our Form 10-Q filed on November 14, 2007 as Exhibit 10.3. | |||
10 | .3 | Form of indemnity agreement entered into with directors of us, our chief financial officer and company secretary | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.3. | |||
10 | .4 | Lease of premises 1 Corporate Avenue, Rowville Victoria Australia by and between Universal Biosensors Pty Ltd and Heyram Properties Pty Ltd. | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.5. | |||
10 | .5 | AusIndustry, R&D Start Program Agreement, effective February 25, 2005 (particular and general conditions) | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.6. | |||
10 | .6 | Employee Option Plan | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.7 | |||
10 | .7 | Employment agreement between Universal Biosensors Pty Ltd and Mr. Salesh Balak effective November 27, 2006 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.8 | |||
10 | .8 | Employment agreement between Universal Biosensors Pty Ltd and Mr. Garry Chambers effective April 1, 2006 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.9 | |||
10 | .9 | Employment agreement between Universal Biosensors Pty Ltd and Dr Ronald Chatelier dated April 1, 2006 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.10 |
Exhibit |
||||||
Number |
Description
|
Location
|
||||
10 | .10 | Employment agreement between Universal Biosensors Pty Ltd and Dr Alastair Hodges effective April 1, 2006 | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.11 | |||
10 | .11 | Employment agreement between Universal Biosensors Pty Ltd and Mr. Adrian Oates dated August 15, 2007 | Incorporated by reference to our Form 10-K filed on March 16, 2010 as Exhibit 10.12 | |||
10 | .12 | Master Services and Supply Agreement by and between Universal Biosensors Pty Ltd, Universal Biosensors, Inc. and LifeScan, Inc. dated October 29, 2007 | Incorporated by reference to our Quarterly Report on Form 10-Q filed on November 14, 2007 as Exhibit 10.1. Confidentiality treatment has been granted for portions of this exhibit. These confidential portions have been omitted and were filed separately with the SEC. | |||
10 | .13 | First Amendment to the Master services and Supply Agreement dated December 11, 2008 (which amends the Master Services and Supply Agreement by and between Universal Biosensors Pty Ltd, Universal Biosensors, Inc. and LifeScan, Inc. dated October 29, 2007 and filed on November 14, 2007 as Exhibit 10.1 to our Quarterly Report on Form 10-Q) | Incorporated by reference to our Annual Report on Form 10-K filed on March 30, 2009 as Exhibit 10.14 | |||
10 | .14 | Second Services Addendum - manufacturing Process Support (which amends the Master Services and Supply Agreement by and between Universal Biosensors Pty Ltd, Universal Biosensors, Inc. and LifeScan, Inc. dated October 29, 2007 incorporated by reference to our Quarterly Report on Form 10-Q filed on November 14, 2007 as Exhibit 10.1.) | Incorporated by reference to our Annual Report on Form 10-K filed on March 30, 2009 as Exhibit 10.15 | |||
10 | .15 | Advanced Care Enhanced Product Agreement (which is an addendum to the Amended and Restated Master Services and Supply Agreement filed on August 7, 2009 as Exhibit 10.3 to our Quarterly Report on Form 10-Q) | Incorporated by reference to our Quarterly Report on Form 10-Q filed on August 7, 2009 as Exhibit 10.1. Confidentiality treatment has been granted for portions of this exhibit. These confidential portions have been omitted and were filed separately with the SEC. |
Exhibit |
||||||
Number |
Description
|
Location
|
||||
10 | .16 | Fifth Amendment to Development and Research Agreement (which amends the Development and Research Agreement by and between Universal Biosensors, Inc. and LifeScan, Inc. dated April 1, 2002 and filed on April 30, 2007 as Exhibit 10.2 to our Form 10, the Amendment to the Development and Research Agreement filed on June 12 as Exhibit 10.2 to Amendment No. 2 to our Form 10 and the Amendment to Development and Research Agreement filed on November 14, 2007 as Exhibit 10.3 to our Quarterly Report on Form 10-Q. | Incorporated by reference to our Quarterly Report on Form 10-Q filed on August 7, 2009 as Exhibit 10.2. | |||
10 | .17 | Amended and Restated Master Services and Supply Agreement (which amends and restates the Master Services and Supply Agreement by and between Universal Biosensors Pty. Ltd., Universal Biosensors, Inc., and LifeScan, Inc. dated October 29, 2007 filed on November 14, 2007 as Exhibit 10.1 to our Quarterly Report on Form 10-Q and the First Amendment to the Master Services and Supply Agreement filed on March 30, 2009 as Exhibit 10.14 to our Annual Report on Form 10-K) | Incorporated by reference to our Quarterly Report on Form 10-Q filed on August 7, 2009 as Exhibit 10.3. Confidentiality treatment has been granted for portions of this exhibit. These confidential portions have been omitted and were filed separately with the SEC. | |||
10 | .18 | Manufacturing Initiation Payment Addendum to Master Services and Supply Agreement (which is an addendum to the Amended and Restated Master Services and Supply Agreement filed on August 7, 2009 as Exhibit 10.3 to our Quarterly Report on Form 10-Q) | Incorporated by reference to our Quarterly Report on Form 10-Q filed on August 7, 2009 as Exhibit 10.4. Confidentiality treatment has been granted for portions of this exhibit. These confidential portions have been omitted and were filed separately with the SEC. | |||
10 | .19 | Employment agreement between Universal Biosensors Pty Ltd and Mr. Andrew Denver dated September 9, 2010 | Incorporated by reference to our Current Report on Form 8-K/A filed on December 22, 2010 as Exhibit 10.1. | |||
13 | .0 | Annual Report | Filed herewith | |||
14 | .0 | Code of Ethics | Incorporated by reference to our Annual Report on Form 10-K filed on March 28, 2008 as Exhibit 14.0 | |||
21 | .0 | List of Subsidiaries | Incorporated by reference to our General Form for Registration of Securities on Form 10 filed on April 30, 2007 as Exhibit 21.0 | |||
24 | .0 | Power of Attorney | Included on signature page |
Exhibit |
||||||
Number |
Description
|
Location
|
||||
31 | .1 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act | Filed herewith | |||
31 | .2 | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act | Filed herewith | |||
32 | .0 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act | Filed herewith |
F-2 | ||||
F-11 | ||||
F-13 | ||||
F-14 | ||||
F-15 | ||||
F-16 | ||||
F-17 | ||||
F-38 |
F-1
F-2
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Revenue
|
11,760,009 | 132,733 | | |||||||||
Cost of goods sold
|
(10,801,062 | ) | (458,162 | ) | | |||||||
958,947 | (325,429 | ) | | |||||||||
Quarters Ended | ||||||||||||||||
December 31 | September 30 | June 30 | March 31 | |||||||||||||
A$ | A$ | A$ | A$ | |||||||||||||
Revenue
|
5,672,739 | 3,202,873 | 1,359,584 | 1,524,813 | ||||||||||||
Cost of goods sold
|
(4,189,520 | ) | (3,136,390 | ) | (1,936,716 | ) | (1,538,436 | ) | ||||||||
1,483,219 | 66,483 | (577,132 | ) | (13,623 | ) | |||||||||||
| Contract research and development we undertake contract research and development in the area of diabetes management for LifeScan. Contract research and development revenue up to the 2009 financial year has been recorded under the caption Research and development income. As we commenced commercial production in 2010, the research and development was seen more as a service we provide to LifeScan which meant presenting it within Revenue from Services; | |
| Product enhancement a service fee based on the number of strips sold by LifeScan is payable to us as an ongoing reward for our services and efforts to enhance the product; | |
| Other services ad-hoc services provided on an agreed basis based on LifeScans requirements. |
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Revenue from services
|
6,420,027 | 2,850,071 | 3,121,754 | |||||||||
Cost of services
|
(1,481,674 | ) | (169,241 | ) | (3,121,754 | ) | ||||||
4,938,353 | 2,680,830 | | ||||||||||
Income Research and development income
|
| 1,337,125 | 1,170,190 |
F-3
| consultant and employee related expenses, which include consulting fees, salary and benefits; | |
| materials and consumables acquired for the research and development activities; | |
| external research and development expenses incurred under agreements with third party organizations and universities; and | |
| facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment and laboratory and other supplies. | |
| Our research and development activities can be described as follows: |
(a) | Blood glucose |
(b) | Blood coagulation |
(c) | Immunoassay |
F-4
(d) | DNA/RNA |
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Research and development expenses
|
6,482,150 | 14,898,072 | 11,885,871 | |||||||||
Research grants received recognized against related research and
development expenses
|
| | (300,613 | ) | ||||||||
Research and development expenses as reported
|
6,482,150 | 14,898,072 | 11,585,258 | |||||||||
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
General and administrative expenses
|
7,185,550 | 5,635,569 | 5,510,127 | |||||||||
F-5
(a) | Revenue Recognition |
(b) | Stock-Based Compensation |
F-6
(c) | Research and Development Expenditure |
(d) | Income Taxes |
(e) | Impairment of Long-Lived Assets |
F-7
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Financial assets:
|
||||||||||||
Cash and cash equivalents
|
23,271,766 | 31,291,011 | 28,334,864 | |||||||||
Accounts receivables
|
3,588,798 | 415,397 | 31,657 | |||||||||
Total financial assets
|
26,860,564 | 31,706,408 | 28,366,521 | |||||||||
Debt:
|
||||||||||||
Short and long term debt/borrowings
|
| | | |||||||||
Total debt
|
| | | |||||||||
Net financial assets
|
26,860,564 | 31,706,408 | 28,366,521 | |||||||||
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Cash and cash equivalents
|
23,271,766 | 31,291,011 | 28,334,864 | |||||||||
Working capital
|
26,250,899 | 32,118,842 | 30,845,011 | |||||||||
Ratio of current assets to current liabilities
|
6.89 : 1 | 13.05 : 1 | 17.19 : 1 | |||||||||
Shareholders equity per common share
|
0.30 | 0.33 | 0.31 |
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Cash provided by/(used in):
|
||||||||||||
Operating activities
|
(6,414,248 | ) | 5,867,156 | (7,140,386 | ) | |||||||
Investing activities
|
(2,320,293 | ) | (2,990,007 | ) | (6,471,419 | ) | ||||||
Financing activities
|
715,296 | 78,998 | (11,616 | ) | ||||||||
Net increase/(decrease) in cash and cash equivalents
|
(8,019,245 | ) | 2,956,147 | (13,623,421 | ) | |||||||
F-8
A$ | ||||
Less than 1 year
|
537,526 | |||
1 3 years
|
1,124,013 | |||
3 5 years
|
146,312 | |||
More than 5 years
|
| |||
Total minimum lease payments
|
1,807,851 | |||
Payments Due by Period | ||||||||||||||||||||
Less Than |
More Than |
|||||||||||||||||||
Total | 1 Year | 13 Years | 35 Years | 5 Years | ||||||||||||||||
A$ | A$ | A$ | A$ | A$ | ||||||||||||||||
Long-Term Debt Obligations
|
| | | | | |||||||||||||||
Asset Retirement Obligations(1)
|
1,998,060 | | | 1,998,060 | | |||||||||||||||
Operating Lease Obligations(2)
|
1,807,851 | 537,526 | 1,124,013 | 146,312 | | |||||||||||||||
Purchase Obligations(3)
|
5,402,250 | 5,402,250 | | | | |||||||||||||||
Other Long-Term Liabilities on
|
||||||||||||||||||||
Balance Sheet under GAAP(4)
|
160,675 | | 100,509 | 58,235 | 1,931 | |||||||||||||||
Total
|
9,368,836 | 5,939,776 | 1,224,522 | 2,202,607 | 1,931 | |||||||||||||||
(1) | Represents legal obligations associated with the retirement and removal of long-lived assets. | |
(2) | Our operating lease obligations relate primarily to the lease of our premises. | |
(3) | Represents outstanding purchase orders | |
(4) | Represents long service leave owing to the employees. |
F-9
F-10
F-11
F-12
December 31, |
December 31, |
|||||||
2010 | 2009 | |||||||
A$ | A$ | |||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
23,271,766 | 31,291,011 | ||||||
Inventories, net
|
3,191,093 | 305,124 | ||||||
Accrued income
|
| 118,305 | ||||||
Accounts receivable
|
3,588,798 | 415,397 | ||||||
Prepayments
|
303,181 | 2,289,149 | ||||||
Other current assets
|
356,196 | 364,339 | ||||||
Total current assets
|
30,711,034 | 34,783,325 | ||||||
Property, plant and equipment
|
32,713,280 | 27,898,099 | ||||||
Less accumulated depreciation
|
(9,586,365 | ) | (6,597,956 | ) | ||||
Property, plant and equipment net
|
23,126,915 | 21,300,143 | ||||||
Total assets
|
53,837,949 | 56,083,468 | ||||||
LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
Current liabilities:
|
||||||||
Accounts payable
|
1,764,364 | 434,207 | ||||||
Accrued expenses
|
2,099,477 | 1,201,893 | ||||||
Financial instruments
|
| 47,412 | ||||||
Deferred income
|
| 559,931 | ||||||
Employee entitlements provision
|
596,294 | 421,040 | ||||||
Total current liabilities
|
4,460,135 | 2,664,483 | ||||||
Non-current liabilities:
|
||||||||
Asset retirement obligations
|
1,998,060 | 1,842,547 | ||||||
Employee entitlements provision
|
160,675 | 262,436 | ||||||
Total non-current liabilities
|
2,158,735 | 2,104,983 | ||||||
Total liabilities
|
6,618,870 | 4,769,466 | ||||||
Commitments and contingencies (Note 3)
|
| | ||||||
Stockholders equity:
|
||||||||
Preferred stock, $0.01 par value. Authorized
1,000,000 shares; issued and outstanding nil in 2010 (2009:
nil)
|
||||||||
Common stock, $0.0001 par value. Authorized
300,000,000 shares; issued and outstanding
158,871,495 shares in 2010 (2009: 157,155,933)
|
15,887 | 15,716 | ||||||
Additional paid-in capital
|
77,034,717 | 74,566,698 | ||||||
Accumulated deficit
|
(22,922,688 | ) | (24,353,151 | ) | ||||
Current year earnings/(loss)
|
(6,610,525 | ) | 1,430,463 | |||||
Accumulated other comprehensive income
|
(298,312 | ) | (345,724 | ) | ||||
Total stockholders equity
|
47,219,079 | 51,314,002 | ||||||
Total liabilities and stockholders equity
|
53,837,949 | 56,083,468 | ||||||
F-13
Years Ended December 31, | ||||||||||||
|
2010 | 2009 | 2008 | |||||||||
A$ | A$ | A$ | ||||||||||
Revenue
|
||||||||||||
Revenue from products
|
$ | 11,760,009 | $ | 132,733 | $ | | ||||||
Revenue from services
|
6,420,027 | 2,850,071 | 3,121,754 | |||||||||
Research and development income
|
| 1,337,125 | 1,170,190 | |||||||||
Milestone payment
|
| 17,722,641 | | |||||||||
Total revenue
|
18,180,036 | 22,042,570 | 4,291,944 | |||||||||
Operating costs & expenses
|
||||||||||||
Cost of goods sold(1)
|
10,801,062 | 458,162 | | |||||||||
Cost of services
|
1,481,674 | 169,241 | 3,121,754 | |||||||||
Research and development (2 and 3)
|
6,482,150 | 14,898,072 | 11,585,258 | |||||||||
General and administrative(4)
|
7,185,550 | 5,635,569 | 5,510,127 | |||||||||
Total operating costs & expenses
|
25,950,436 | 21,161,044 | 20,217,139 | |||||||||
Profit/(loss) from operations
|
(7,770,400 | ) | 881,526 | (15,925,195 | ) | |||||||
Other income/(expense)
|
||||||||||||
Interest income
|
1,192,889 | 809,459 | 2,542,060 | |||||||||
Interest expense
|
| (9,636 | ) | (9,489 | ) | |||||||
Fee income
|
| | 1,131,222 | |||||||||
Other
|
(33,014 | ) | (250,886 | ) | 265,310 | |||||||
Total other income/(expense)
|
1,159,875 | 548,937 | 3,929,103 | |||||||||
Net profit/(loss) before tax
|
(6,610,525 | ) | 1,430,463 | (11,996,092 | ) | |||||||
Income tax benefit/(expense)
|
| | 206 | |||||||||
Net profit/(loss)
|
$ | (6,610,525 | ) | $ | 1,430,463 | $ | (11,995,886 | ) | ||||
Basic net profit/(loss) per share
|
$ | (0.04 | ) | $ | 0.01 | $ | (0.08 | ) | ||||
Average weighted number of shares used as denominator in
calculating basic net profit/(loss) per share
|
157,584,044 | 157,013,578 | 156,970,679 | |||||||||
Diluted net profit/(loss) per share
|
$ | (0.04 | ) | $ | 0.01 | $ | (0.08 | ) | ||||
Average weighted number of shares used as denominator in
calculating diluted net profit/(loss) per share
|
157,584,044 | 161,354,802 | 156,970,679 | |||||||||
Notes:
|
||||||||||||
1 Includes non-cash compensation expense (cost of goods
sold)
|
$ | 168,512 | $ | 21,207 | $ | | ||||||
2 Net of research grant income in these amounts
|
$ | | $ | | $ | 300,613 | ||||||
3 Includes non-cash compensation expense (research and
development)
|
$ | 859,551 | $ | 653,474 | $ | 661,497 | ||||||
4 Includes non-cash compensation expense (general and
administrative)
|
$ | 648,940 | $ | 404,090 | $ | 299,611 |
F-14
Additional |
Other |
Total |
||||||||||||||||||||||
Ordinary Shares |
Paid-in |
Accumulated |
Comprehensive |
Stockholders |
||||||||||||||||||||
|
Shares | Amount | Capital | Deficit | Income | Equity | ||||||||||||||||||
A$ | A$ | A$ | A$ | A$ | ||||||||||||||||||||
Balances at January 1, 2008
|
156,958,812 | 15,696 | 72,389,505 | (12,357,265 | ) | (298,312 | ) | 59,749,624 | ||||||||||||||||
Transaction costs on shares issued
|
| | (16,663 | ) | | | (16,663 | ) | ||||||||||||||||
Comprehensive income
|
||||||||||||||||||||||||
Net loss
|
| | | (11,995,886 | ) | | (11,995,886 | ) | ||||||||||||||||
Total Comprehensive income
|
(11,995,886 | ) | ||||||||||||||||||||||
Exercise of stock options issued to employees
|
18,124 | 2 | 5,045 | | | 5,047 | ||||||||||||||||||
Stock option expense
|
| | 961,108 | | | 961,108 | ||||||||||||||||||
Balances at December 31, 2008
|
156,976,936 | 15,698 | 73,338,995 | (24,353,151 | ) | (298,312 | ) | 48,703,230 | ||||||||||||||||
Comprehensive Income
|
||||||||||||||||||||||||
Loss on derivatives and hedges, net of tax
|
| | | | (47,412 | ) | (47,412 | ) | ||||||||||||||||
Net profit
|
| | | 1,430,463 | | 1,430,463 | ||||||||||||||||||
Total Comprehensive income
|
1,383,051 | |||||||||||||||||||||||
Exercise of stock options issued to employees
|
138,327 | 14 | 78,984 | | | 78,998 | ||||||||||||||||||
Shares issued to employees
|
40,670 | 4 | 69,948 | | | 69,952 | ||||||||||||||||||
Stock option expense
|
| | 1,078,771 | | | 1,078,771 | ||||||||||||||||||
Balances at December 31, 2009
|
157,155,933 | 15,716 | 74,566,698 | (22,922,688 | ) | (345,724 | ) | 51,314,002 | ||||||||||||||||
Comprehensive income
|
||||||||||||||||||||||||
Gain on derivatives and hedges, net of tax
|
| | | | 47,412 | 47,412 | ||||||||||||||||||
Net loss
|
| | | (6,610,525 | ) | | (6,610,525 | ) | ||||||||||||||||
Total Comprehensive income
|
(6,563,113 | ) | ||||||||||||||||||||||
Exercise of stock options issued to employees
|
1,667,581 | 167 | 715,129 | | | 715,296 | ||||||||||||||||||
Shares issued to employees
|
47,981 | 4 | 75,887 | | | 75,891 | ||||||||||||||||||
Stock option expense
|
| | 1,677,003 | | | 1,677,003 | ||||||||||||||||||
Balances at December 31, 2010
|
158,871,495 | 15,887 | 77,034,717 | (29,533,213 | ) | (298,312 | ) | 47,219,079 | ||||||||||||||||
F-15
Years Ended December 31, | ||||||||||||
|
2010 | 2009 | 2008 | |||||||||
A$ | A$ | A$ | ||||||||||
Cash flows from operating activities provided by/(used
in):
|
||||||||||||
Net profit/(loss)
|
(6,610,525 | ) | 1,430,463 | (11,995,886 | ) | |||||||
Adjustments to reconcile net profit/(loss) to net cash provided
by/(used in) operating activities:
|
||||||||||||
Depreciation and impairment of plant and equipment
|
2,990,858 | 2,851,285 | 2,266,847 | |||||||||
Share based payments expense
|
1,677,003 | 1,078,771 | 961,108 | |||||||||
Loss on fixed assets disposal
|
2,618 | 60,658 | 34,207 | |||||||||
Change in assets and liabilities:
|
||||||||||||
Inventory
|
(2,885,969 | ) | (305,124 | ) | 486,633 | |||||||
Accounts receivables
|
(3,733,332 | ) | (114,713 | ) | 439,691 | |||||||
Prepaid expenses and other current assets
|
(6,079 | ) | 141,331 | 191,728 | ||||||||
Accrued income
|
118,305 | | (38,494 | ) | ||||||||
Income tax payable
|
| | (18,000 | ) | ||||||||
Deferred revenue
|
| 290,904 | | |||||||||
Employee entitlements
|
73,493 | 50,192 | 264,286 | |||||||||
Accounts payable and accrued expenses
|
1,959,380 | 383,389 | 267,494 | |||||||||
Net cash provided by/(used in) operating activities
|
(6,414,248 | ) | 5,867,156 | (7,140,386 | ) | |||||||
Cash flows from investing activities:
|
||||||||||||
Proceeds/(purchases) from sale of investment securities
|
| | 3,123,501 | |||||||||
Instalment payments to acquire plant and equipment
|
(988,334 | ) | (2,145,808 | ) | (3,616,235 | ) | ||||||
Purchases of property, plant and equipment
|
(1,331,959 | ) | (844,199 | ) | (5,978,685 | ) | ||||||
Net cash used in investing activities
|
(2,320,293 | ) | (2,990,007 | ) | (6,471,419 | ) | ||||||
Cash flows from financing activities:
|
||||||||||||
Transaction costs on share issue
|
| | (16,663 | ) | ||||||||
Proceeds from borrowings
|
| 479,673 | | |||||||||
Repayment of borrowings
|
| (479,673 | ) | | ||||||||
Proceeds from stock options exercised
|
715,296 | 78,998 | 5,047 | |||||||||
Net cash provided by/(used in) financing activities
|
715,296 | 78,998 | (11,616 | ) | ||||||||
Net increase/(decrease) in cash and cash equivalents
|
(8,019,245 | ) | 2,956,147 | (13,623,421 | ) | |||||||
Cash and cash equivalent at beginning of period
|
31,291,011 | 28,334,864 | 41,958,285 | |||||||||
Effect of exchange rate fluctuations on the balances of cash
held in foreign currencies
|
| | | |||||||||
Cash and cash equivalents at end of period
|
23,271,766 | 31,291,011 | 28,334,864 | |||||||||
F-16
(1) | Basis of Presentation |
(2) | Summary of Significant Accounting Policies |
F-17
F-18
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Raw materials at cost
|
2,798,045 | 289,069 | | |||||||||
Work in progress at cost
|
188,629 | 16,055 | | |||||||||
Finished goods at cost
|
204,419 | | | |||||||||
3,191,093 | 305,124 | | ||||||||||
F-19
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Research and development expenses
|
6,482,150 | 14,898,072 | 11,885,871 | |||||||||
Research grants received recognized against related research and
development expenses
|
| | (300,613 | ) | ||||||||
Research and development expenses as reported
|
6,482,150 | 14,898,072 | 11,585,258 | |||||||||
F-20
Years Ended December 31, | ||||||||
2010 | 2009 | |||||||
A$ | A$ | |||||||
Opening balance at January 1
|
1,842,547 | 1,699,133 | ||||||
Accretion expense
|
155,513 | 143,414 | ||||||
Ending balance at December 31
|
1,998,060 | 1,842,547 | ||||||
| Market approach based on market prices and other information from market transactions involving identical or comparable assets or liabilities. | |
| Cost approach based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence. | |
| Income approach based on the present value of a future stream of net cash flows |
| Quoted prices for identical assets or liabilities in active markets (Level 1 inputs) | |
| Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs) | |
| Unobservable inputs that reflect estimates and assumptions (Level 3 inputs) |
F-21
| milestone payment. The Company received a milestone payment of A$17,722,641 in December 2009 triggered by the first grant to LifeScan of regulatory clearance to sell the blood glucose product; | |
| contract manufacturing. One of two pricing methodologies will apply depending on whether we are manufacturing above or below a specified quantity of blood glucose tests strips in a quarter. If less than the specified quantity of test strips is produced within a quarter, we are considered to be in the interim costing period. In the interim costing period, the Company is not expected to generate manufacturing profit, but is expected to recover most of its glucose manufacturing costs. As manufactured volumes increase beyond the specified quantity of blood glucose test strips per quarter, the interim costing period will cease to apply and a different pricing methodology will apply, at which time we expect our blood glucose manufacturing operations to be profitable. We ceased to be in the interim costing period during the second half of 2010 at which time we generated profits from our blood glucose manufacturing operations; and | |
| product enhancement. A service fee based on the number of strips sold by LifeScan is payable to us as an ongoing reward for our services and efforts to enhance the product. |
F-22
| the Company was responsible for providing the service and was also the primary obligor with respect to purchasing goods and services from third party suppliers which in turn were used to provide services to LifeScan; |
F-23
| the Company had unmitigated general inventory risk; | |
| the Company had credit risk; and | |
| pricing was not fixed but determined by the level of activity. |
F-24
F-25
| assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet; | |
| income and expenses for each income statement are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and | |
| all resulting exchange differences are recognized as a separate component of equity. |
F-26
F-27
(3) | Commitments and Contingent Liabilities |
A$ | ||||
2011
|
537,526 | |||
2012
|
556,082 | |||
2013
|
567,931 | |||
2014
|
146,312 | |||
2015 and thereafter
|
| |||
Total minimum lease payments
|
1,807,851 | |||
F-28
(4) | Income Taxes |
F-29
Years Ended December 31, | ||||||||||||||||||||||||
2010 | 2009 | 2008 | ||||||||||||||||||||||
$ | % | $ | % | $ | % | |||||||||||||||||||
Profit/(loss) before income taxes
|
(6,610,525 | ) | 1,430,463 | (11,996,092 | ) | |||||||||||||||||||
Computed by applying income tax rate of home jurisdiction
|
(1,983,157 | ) | 30 | 429,139 | 30 | (3,598,828 | ) | 30 | ||||||||||||||||
Research & development incentive
|
(421,341 | ) | 6 | (3,524,333 | ) | (246 | ) | (702,124 | ) | 6 | ||||||||||||||
Disallowed expenses/(income):
|
||||||||||||||||||||||||
Share based payment
|
503,100 | (7 | ) | 323,631 | 22 | 288,332 | (3 | ) | ||||||||||||||||
Other
|
4,730 | | (226,924 | ) | (16 | ) | 2,600 | | ||||||||||||||||
Change in valuation allowance
|
1,896,668 | (29 | ) | 2,998,487 | 210 | 4,010,020 | (33 | ) | ||||||||||||||||
Adjustment in respect of current income tax of prior years
|
| | | | (206 | ) | | |||||||||||||||||
Income tax expense/(benefit)
|
| | | | (206 | ) | | |||||||||||||||||
As of December 31, | ||||||||
2010 | 2009 | |||||||
Deferred tax assets:
|
||||||||
Operating loss carry forwards
|
12,925,915 | 10,903,873 | ||||||
Unamortized capital raising cost
|
104,850 | 352,651 | ||||||
Depreciation and amortization
|
(143,647 | ) | (392,582 | ) | ||||
Asset retirement obligations
|
46,654 | 43,024 | ||||||
Employee entitlements
|
227,090 | 205,043 | ||||||
Other accruals
|
807,922 | 587,802 | ||||||
Total deferred tax assets
|
13,968,784 | 11,699,811 | ||||||
Valuation allowance for deferred tax assets
|
(13,968,784 | ) | (11,699,811 | ) | ||||
Net deferred tax asset
|
| | ||||||
(5) | Employee Incentive Schemes |
(a) | Stock Option Plan |
F-30
Grant Date | ||||||||||||||||||||||||||||||||||||||||
Nov-10
|
Nov-10 | Feb-10 | Nov-09 | Jun-09 | Jun-09 | May-09 | Feb-09 | Aug-08 | Mar-08 | |||||||||||||||||||||||||||||||
Exercise Price (A$)
|
Nil | $ | 1.58 | $ | 1.60 | $ | 1.72 | Nil | $ | 0.94 | Nil | $ | 0.50 | $ | 0.70 | $ | 0.89 | |||||||||||||||||||||||
Share Price at Grant Date (A$)
|
$ | 1.58 | $ | 1.58 | $ | 1.60 | $ | 1.73 | $ | 0.95 | $ | 0.95 | $ | 1.18 | $ | 0.43 | $ | 0.71 | $ | 0.91 | ||||||||||||||||||||
Volatility
|
72 | % | 72 | % | 77 | % | 78 | % | 80 | % | 80 | % | 81 | % | 77 | % | 71 | % | 76 | % | ||||||||||||||||||||
Expected Life
|
7 years | 7 years | 7 years | 10 years | 10 years | 10 years | 10 years | 10 years | 10 years | 10 years | ||||||||||||||||||||||||||||||
Risk Free Interest Rate
|
5.27 | % | 5.27 | % | 5.34 | % | 5.63 | % | 5.49 | % | 5.49 | % | 4.87 | % | 4.26 | % | 5.85 | % | 5.87 | % | ||||||||||||||||||||
Fair Value of Option (A$)
|
$ | 1.58 | $ | 0.96 | $ | 0.99 | $ | 1.13 | $ | 0.95 | $ | 0.62 | $ | 1.04 | $ | 0.28 | $ | 0.45 | $ | 0.59 |
F-31
Weighted |
||||||||
Number of |
Average |
|||||||
Shares | Exercise Price | |||||||
A$ | ||||||||
Balance at December 31, 2009
|
10,039,486 | 0.85 | ||||||
Granted
|
914,500 | 1.12 | ||||||
Exercised
|
(1,667,581 | ) | 0.49 | |||||
Lapsed
|
(746,701 | ) | 1.12 | |||||
Balance at December 31, 2010
|
8,539,704 | 0.93 | ||||||
Options Outstanding | ||||||||||||||||
Weighted |
||||||||||||||||
Average |
Options |
|||||||||||||||
Remaining |
Exercisable |
|||||||||||||||
Exercise Price
|
Shares | Life in Years | Shares | |||||||||||||
A$ | ||||||||||||||||
2010 | $0.30 | 1,556,770 | 3.00 | 1,556,770 | ||||||||||||
$0.35 | 453,099 | 5.00 | 453,099 | |||||||||||||
$1.18 | 623,000 | 6.20 | 623,000 | |||||||||||||
$1.20 | 590,000 | 6.70 | 590,000 | |||||||||||||
$0.89 | 874,000 | 7.20 | 874,000 | |||||||||||||
$0.70 | 275,334 | 7.60 | 179,997 | |||||||||||||
$0.50 | 120,000 | 8.10 | 78,665 | |||||||||||||
Nil | 79,167 | 8.40 | 45,833 | |||||||||||||
$0.94 | 1,261,667 | 8.50 | 836,011 | |||||||||||||
Nil | 434,167 | 8.50 | 54,167 | |||||||||||||
$1.72 | 1,700,000 | 8.90 | 600,006 | |||||||||||||
$1.60 | 50,000 | 6.10 | 16,666 | |||||||||||||
$1.58 | 422,500 | 6.90 | | |||||||||||||
Nil | 100,000 | 6.90 | |
F-32
Number of Options |
||||||||||||
Exercised and |
||||||||||||
Corresponding |
||||||||||||
Number of Shares |
Weighted Average |
Proceeds |
||||||||||
Period Ending
|
Issued | Exercise Price | Received | |||||||||
A$ | A$ | |||||||||||
2008
|
18,124 | 0.35 | 5,047 | |||||||||
2009
|
138,327 | 0.60 | 78,998 | |||||||||
2010
|
1,667,581 | 0.49 | 715,296 | |||||||||
Total
|
1,824,032 | 799,341 | ||||||||||
(b) | Restricted Share Plan |
Market |
||||||||
Number of |
Value of |
|||||||
Restricted |
Restricted |
|||||||
Shares Issued | Shares Issued | |||||||
November, 2009
|
40,670 | A$ | 69,952 | |||||
May, 2010
|
581 | A$ | 999 | |||||
November, 2010
|
47,400 | A$ | 74,892 |
(6) | Related Party Transactions |
F-33
As of December, 31 | ||||||||
2010 | 2009 | |||||||
A$ | A$ | |||||||
Current Receivables
|
||||||||
Sale of goods
|
3,588,798 | 396,378 | ||||||
Sale of services
|
| 19,019 | ||||||
3,588,798 | 415,397 | |||||||
Revenue
|
||||||||
Revenue from products
|
11,760,009 | 132,733 | ||||||
Revenue from services
|
6,420,027 | 2,850,071 | ||||||
Research and development income
|
| 1,337,125 | ||||||
Milestone payment
|
| 17,722,641 | ||||||
18,180,036 | 22,042,570 | |||||||
(7) | Financial Instruments |
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Financial assets:
|
||||||||||||
Cash and cash equivalents
|
23,271,766 | 31,291,011 | 28,334,864 | |||||||||
Accounts receivables
|
3,588,798 | 415,397 | 31,657 | |||||||||
Total financial assets
|
26,860,564 | 31,706,408 | 28,366,521 | |||||||||
Debt:
|
||||||||||||
Short and long term debt/borrowings
|
| | | |||||||||
Total debt
|
| | | |||||||||
Net financial assets
|
26,860,564 | 31,706,408 | 28,366,521 | |||||||||
F-34
(8) | Property, Plant and Equipment |
As of December, 31 | ||||||||
2010 | 2009 | |||||||
A$ | A$ | |||||||
Plant and equipment
|
15,110,554 | 13,271,715 | ||||||
Leasehold improvements
|
8,810,036 | 8,328,270 | ||||||
Capital work in process
|
8,792,690 | 6,298,114 | ||||||
32,713,280 | 27,898,099 | |||||||
Accumulated depreciation
|
(9,586,365 | ) | (6,597,956 | ) | ||||
Property, plant & equipment, net
|
23,126,915 | 21,300,143 | ||||||
(9) | Accrued Expenses |
As of December, 31 | ||||||||
2010 | 2009 | |||||||
A$ | A$ | |||||||
Legal, tax and accounting fees
|
591,184 | 176,000 | ||||||
Salary and related on-costs
|
587,695 | 327,665 | ||||||
Research and development materials
|
120,000 | 698,228 | ||||||
Inventory
|
657,142 | | ||||||
Other
|
143,456 | | ||||||
2,099,477 | 1,201,893 | |||||||
(10) | Stockholders Equity Common Stock |
F-35
(11) | Retirement Benefits |
(12) | Net Profit/(Loss) per Share |
Years Ended December 31, | ||||||||||||
2010 | 2009 | 2008 | ||||||||||
A$ | A$ | A$ | ||||||||||
Weighted average number of ordinary shares used as denominator
in calculating:
|
||||||||||||
Basic net profit/(loss) per share
|
157,584,044 | 157,013,578 | 156,970,679 | |||||||||
Diluted net profit/(loss) per share
|
157,584,044 | 161,354,802 | 156,970,679 | |||||||||
(13) | Guarantees and Indemnifications |
F-36
| indemnify the relevant officers and directors for certain expenses, judgments, fines and settlement amounts incurred by them in connection with their services as an officer or director of the Company or its subsidiaries; and | |
| require the Company to make a good faith determination whether or not it is practicable to maintain liability insurance for officers and directors or to ensure the Companys performance of its indemnification obligations under the agreements. |
(14) | Segments |
(15) | Deed of Cross Guarantee |
F-37
Additions | ||||||||||||||||||||
Balance at |
Charged to |
Charged to |
||||||||||||||||||
Beginning of |
Costs and |
Other |
Balance at |
|||||||||||||||||
Period | Expenses | Accounts | Deductions | End of Period | ||||||||||||||||
A$ | A$ | A$ | A$ | A$ | ||||||||||||||||
Year ended December 31, 2008
|
||||||||||||||||||||
Deferred income tax valuation allowance
|
6,080,529 | 4,010,020 | 510,571 | | 10,601,120 | |||||||||||||||
Year ended December 31, 2009
|
||||||||||||||||||||
Deferred income tax valuation allowance
|
10,601,120 | 2,998,487 | | (1,899,796 | ) | 11,699,811 | ||||||||||||||
Year ended December 31, 2010
|
||||||||||||||||||||
Deferred income tax valuation allowance
|
11,699,811 | 1,896,668 | 372,305 | | 13,968,784 |
F-38
1. | I have reviewed this report on Form 10-K of Universal Biosensors, Inc.; | |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | ||
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | ||
c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | ||
d) | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and | ||
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
1. | I have reviewed this report on Form 10-K of Universal Biosensors, Inc.; | |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | ||
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | ||
c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | ||
d) | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and | ||
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | ||
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. The undersigned have executed this Certificate as of the 10th day of March 2011. |
/s/ Andrew Denver | ||||
Andrew Denver | ||||
Principal Executive Officer | ||||
/s/ Salesh Balak | ||||
Salesh Balak | ||||
Principal Financial Officer | ||||
* | This certification is being furnished as required by Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended (the Exchange Act), and Section 1350 of Chapter 63 of Title 18 of the United States Code, and shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent such certification is explicitly incorporated by reference in such filing. |